

VIREXX MEDICAL CORP  
Form 6-K  
December 05, 2007

---

---

**FORM 6-K**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

For the month ended                      Commission File Number  
December 2007                              1-32608

**VIREXX MEDICAL CORP.**  
(Translation of registrant's name into English)

8223 Roper Road NW, Edmonton, Alberta, Canada T6E  
6S4  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form                      Form  
20-F                      x                      40-F                      o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):       

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):       

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes    o                      No    x

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

---

---

---

**EXHIBIT INDEX**

Exhibit

NumberDescription of Exhibit

99.1 VIREXX ANNOUNCES PIVOTAL OVAREX® MAb TRIAL RESULTS FAIL TO ACHIEVE STATISTICAL SIGNIFICANCE

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**VIREXX MEDICAL CORP.**

Date: December 5, 2007

By: /s/ Brent Johnston

Brent Johnston  
Interim CFO